ZURA BIO LIMITED Basic Shares Outstanding (Weighted Average)
ZURA BIO LIMITED (ZURA) reported Basic Shares Outstanding (Weighted Average) of 126.80 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-11
- ZURA BIO LIMITED weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 126.80M shares, a 34.48% increase year-over-year.
- ZURA BIO LIMITED weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 112.22M shares, a 20.72% increase year-over-year.
- ZURA BIO LIMITED weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 94.82M shares, a 4.25% increase year-over-year.
- ZURA BIO LIMITED weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 94.56M shares, a 8.28% increase year-over-year.
- ZURA BIO LIMITED weighted average number of shares outstanding, basic for fiscal 2025 was 94.16M shares, a 25.43% increase from fiscal 2024.
- ZURA BIO LIMITED weighted average number of shares outstanding, basic for fiscal 2024 was 75.07M shares, a 127.05% increase from fiscal 2023.
- ZURA BIO LIMITED weighted average number of shares outstanding, basic for fiscal 2023 was 33.06M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 2 month | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 5 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 8 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 11 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 126.80M shares 10-Q · filed 2026-08-11 | 119.55M shares 10-Q · filed 2026-08-11 | 111.28M shares derived: average of 3 quarters · filed 2026-08-11 | 107.10M shares derived: average of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | 112.22M shares 10-Q · filed 2026-05-07 | 103.52M shares derived: average of 2 quarters · filed 2026-05-07 | 100.53M shares derived: average of 3 quarters · filed 2026-05-07 | 98.97M shares derived: average of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | 94.82M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 94.69M shares derived: average of 2 quarters · filed 2026-03-19 | 94.56M shares derived: average of 3 quarters · filed 2026-08-11 | 94.16M shares 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | 94.56M shares 10-Q · filed 2025-11-13 | 94.43M shares derived: average of 2 quarters · filed 2026-08-11 | 93.94M shares 10-Q · filed 2025-11-13 | 93.19M shares derived: average of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | 94.29M shares 10-Q · filed 2026-08-11 | 93.63M shares 10-Q · filed 2026-08-11 | 92.73M shares derived: average of 3 quarters · filed 2026-08-11 | 91.38M shares derived: average of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | 92.96M shares 10-Q · filed 2026-05-07 | 91.96M shares derived: average of 2 quarters · filed 2026-05-07 | 90.42M shares derived: average of 3 quarters · filed 2026-05-07 | 86.55M shares derived: average of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | 90.95M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 89.14M shares derived: average of 2 quarters · filed 2026-03-19 | 84.41M shares derived: average of 3 quarters · filed 2026-03-19 | 75.07M shares 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | 87.34M shares 10-Q · filed 2025-11-13 | 81.14M shares derived: average of 2 quarters · filed 2025-11-13 | 69.78M shares 10-Q · filed 2025-11-13 | 64.06M shares derived: average of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | 74.95M shares 10-Q · filed 2025-08-14 | 60.93M shares 10-Q · filed 2025-08-14 | 56.30M shares derived: average of 3 quarters · filed 2025-08-14 | 53.95M shares derived: average of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | 46.91M shares 10-Q · filed 2025-05-08 | 46.98M shares derived: average of 2 quarters · filed 2025-05-08 | 46.95M shares derived: average of 3 quarters · filed 2025-05-08 | 43.79M shares derived: average of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | 47.05M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | 46.96M shares derived: average of 2 quarters · filed 2025-03-25 | 42.74M shares derived: average of 3 quarters · filed 2025-03-25 | 33.06M shares 10-K · filed 2025-03-25 | ||||
| 2023-09-30 | 46.88M shares 10-Q · filed 2024-11-07 | 40.59M shares derived: average of 2 quarters · filed 2024-11-07 | 28.40M shares 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | 34.30M shares 10-Q · filed 2024-08-13 | 19.01M shares 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | 3.55M shares 10-Q · filed 2024-05-09 | |||||||
| 2022-12-31 | 228.15K shares 10-K · filed 2024-03-28 | |||||||
| 2022-09-30 | 383.48K shares 10-Q · filed 2023-11-13 | 240.24K shares derived: average of 2 quarters · filed 2023-11-13 | 172.33K shares 10-Q · filed 2023-11-13 | |||||
| 2022-06-30 | 97.00K shares 10-Q · filed 2023-08-14 | 53.87K shares 10-Q · filed 2023-08-14 | ||||||
| 2022-03-31 | 108.00 shares 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |